The Food and Drug Administration has warned five manufacturers of drugs for attention-deficit/hyperactivity disorder against using what it terms “false or misleading” promotional materials that overstate the drugs’ efficacy and downplay risks.
The warnings, contained in letters sent in late September to the makers of Adder-all XR, …
Strattera (atomoxetine HCl, Eli Lilly & Co.)
The Food and Drug Administration approved Strattera for attention-deficit/hyperactivity disorder maintenance therapy in children and adolescents aged 6 years and older. This is the first FDA-approved agent for ma…
Strattera (atomoxetine), the first non-stimulant approved for the treatment of attention-deficit hyperactivity disorder is now available by prescription in pharmacies nationwide. Strattera also is approved for treating attention-deficit hyperactivity disorder in adults. For more informatio…
INDIANAPOLIS — Eli Lilly and Co. has received Food and Drug Administration clearance for Strattera (atomoxetine HCl) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective nor…
